CHRS Coherus BioSciences, Inc: רווח למניה ב-12 החודשים האחרונים

This chart of Coherus Biosciences (CHRS) share prices reflects the EPS (TTM) dynamics, which currently stand at 39.20. Coherus Biosciences generates revenue through the sale of antineoplastic agents and biosimilars. Management is actively divesting non-core assets to reduce debt, confirming the transparency of the Loqtorzi rollout. To counter dumping by industry behemoths, the firm is optimizing costs and implementing flexible pricing.
CHRS (Coherus BioSciences Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Coherus Biosciences (CHRS) is currently restructuring its product portfolio, strengthening its biosimilar commercialization team while maintaining its scientific core. The 39.20 metric reflects the percentage change in the rolling annual total of earnings per share, revealing the actual profitability trend. This indicator allows investors to distinguish a temporary price drop from a systemic business decline. An analysis of the YoY net income per share growth over the last 12 months confirms the resilience of the financial model.